N※N

Former FDA Leaders Demand Overhaul After Child's Death

  //food-wine.news-articles.net/content/2026/04/03 .. leaders-demand-overhaul-after-child-s-death.html
  Published in Food and Wine on Friday, April 3rd 2026 at 3:43 GMT by CBS News
      Locale: UNITED STATES

Former FDA Leaders Demand Overhaul of Accelerated Approval Process Following Child's Death

Washington D.C. - April 3, 2026 - A chorus of concern is growing surrounding the Food and Drug Administration's (FDA) accelerated approval process, with twelve former FDA Commissioners and acting Commissioners issuing a scathing joint statement today demanding substantial reforms. The statement, released on Friday, follows the tragic death of 10-year-old Milly Wilkinson, who succumbed to complications believed to be linked to a drug approved through the controversial program earlier this year.

The accelerated approval pathway, designed to expedite access to potentially life-saving treatments for serious and life-threatening conditions, allows the FDA to approve drugs based on surrogate endpoints - preliminary indicators of benefit - requiring manufacturers to conduct further, confirmatory trials after approval to verify the drug's clinical benefit. While hailed by some as a vital mechanism for innovation, critics argue that the system has become dangerously lax, prioritizing speed over rigorous safety and efficacy assessments.

The former FDA leaders' statement doesn't pull punches, asserting that the FDA is experiencing a "serious and systemic failure" in protecting patients. They contend that the agency has become overly reliant on data submitted by pharmaceutical companies, leading to premature approvals and, tragically, patient harm. The death of Milly Wilkinson, diagnosed with a rare genetic disorder, has become the focal point of this intensifying debate.

"We believe that the current accelerated approval process needs to be fundamentally reformed," the statement reads. "The agency must be empowered, and actively utilize that power, to ensure that promises of confirmatory trials are kept and that drugs lacking demonstrable benefit are swiftly removed from the market."

A History of Accelerated Approval & Growing Concerns

The accelerated approval process isn't new. Introduced decades ago, it's facilitated the approval of numerous drugs, particularly in areas like oncology and rare diseases. The intention was noble - to bridge the gap between promising research and patient access. However, the program's effectiveness hinges on the timely and thorough completion of confirmatory trials. Increasingly, observers have noted delays and a lack of aggressive enforcement when companies fail to meet these post-approval obligations. A 2024 report by the Government Accountability Office (GAO) highlighted that, in a significant percentage of cases, confirmatory trials were years overdue, leaving patients using drugs with unverified long-term benefits and potential risks.

The Wilkinson case has intensified these concerns. While the exact details are still under investigation, preliminary reports suggest that the confirmatory trials for the drug she received were not adequately underway at the time of her treatment. This has fueled accusations of negligence and a breakdown in oversight.

Calls for Increased Accountability & Oversight

The former commissioners are proposing a multi-pronged approach to reform. Key recommendations include:

• Stricter Requirements for Confirmatory Trials: Mandating more robust study designs, shorter timelines, and increased statistical power for confirmatory trials.
• Independent Oversight: Establishing an independent body with the authority to review and audit the FDA's accelerated approval decisions, removing potential conflicts of interest.
• Enhanced Enforcement Mechanisms: Giving the FDA greater authority to compel drug companies to complete confirmatory trials and to swiftly withdraw drugs that fail to demonstrate benefit.
• Increased Transparency: Making data from both initial and confirmatory trials publicly available to foster greater accountability and informed decision-making.
• Prioritization of Patient Safety: Shifting the agency's focus from simply accelerating access to treatment to prioritizing the safety and well-being of patients.

Milton Packer, a prominent cardiologist and former member of an FDA advisory committee, echoed these concerns. "The FDA's accelerated approval program has been a major source of innovation in treating serious diseases, but it has also been associated with serious risks," he stated. "This tragedy underscores the need for a more rigorous and transparent process, and a far more aggressive stance towards manufacturers who fail to fulfill their post-approval obligations."

The FDA has acknowledged the mounting criticism and indicated that it is conducting a review of the accelerated approval program. However, the former commissioners argue that these efforts are insufficient and that a fundamental overhaul is necessary to restore public trust and safeguard patient safety. Several lawmakers on both sides of the aisle are now signaling support for legislative action to strengthen the FDA's regulatory authority. Patient advocacy groups are also mobilizing, demanding greater accountability and a commitment to prioritizing patient well-being over pharmaceutical industry interests. The coming months are likely to see intense debate and scrutiny as stakeholders grapple with how to balance the need for innovation with the imperative to protect those who rely on the FDA for safe and effective treatments.